Capricor Therapeutics (CAPR) said Monday the Food and Drug Administration has extended the target action date on its biologics license application for Deramiocel as a treatment for Duchenne muscular dystrophy to Nov. 22 from Aug. 22.
The extension is for the FDA's review of a major amendment to the application, which the company submitted to include additional data from a phase 3 study, Capricor said.
Shares of Capricor Therapeutics were more than 3% higher in Monday trading.
Price: $6.54, Change: $+0.25, Percent Change: +3.97%